The impact of reference pricing on switching behaviour and healthcare utilisation: The case of statins in Germany

European Journal of Health Economics

Volumn 11, Issue 3, 2010, Pages 167-177

  Stargardt, Tom ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Germany; Pharmaceutical care; Reference pricing; Reimbursement; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG COST; DRUG MARKETING; FOLLOW UP; GERMANY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; COMMERCIAL PHENOMENA; COST CONTROL; DECISION MAKING; ECONOMICS; FEE; HEALTH BEHAVIOR; HEALTH SERVICE; HOSPITALIZATION; OUTPATIENT; STATISTICS; UTILIZATION REVIEW;

COMMERCE; COST SAVINGS; DECISION MAKING; GERMANY; HEALTH BEHAVIOR; HEALTH CARE COSTS; HEALTH POLICY; HEALTH SERVICES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OUTPATIENTS; PATIENT COMPLIANCE; PRESCRIPTION FEES;

EID: 77954886499     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0172-3     Document Type: Article

References (30)

1. Puig-Junoy, J.: What is required to evaluate the impact of pharmaceutical reference pricing. Appl. Health Econ. Health Policy 4(2), 87-98 (2005). doi:10.2165/00148365-200504020-00003 (Pubitemid 41324094)
2. Kaló, Z., Muszbek, N., Bodrogi, J., Bidló, J.: Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 80(3), 402-412 (2007). doi: 10.1016/j.healthpol.2006.04. 002 (Pubitemid 46109063)
3. McArthur, W.: Patient outcomes and public health consequences of reference pricing. In: López-Casasnovas, G., Jönsson, B. (eds.) Reference Pricing and Pharmaceutical Policy, pp. 145-160. Springer, Barcelona (2001)
4. Grootendorst, P., Stewart, D.: A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Health Econ. 15(7), 735-742 (2006). doi: 10.1002/hec.1103 (Pubitemid 44057243)
5. Schneeweiss, S., Soumerai, S., Maclure, M., Dormuth, C., Walker, A., Glynn, R.: Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin. Pharmacol. Ther. 74(4), 388-400 (2003). doi:10.1016/ S0009-9236(03)00227-233
6. Schneeweiss, S., Walker, A., Glynn, R., Maclure, M., Dormuth, C., Soumerai, S.: Outcomes of reference pricing for angiotensinconverting- enzyme inhibitors. N. Engl. J. Med. 346(11), 822-829 (2002). doi:10.1056/NEJMsa003087 (Pubitemid 34984656)
7. Grootendorst, P., Marshall, J., Holbrook, A., Dolovich, L., O'Brien, B., Levy, A.: The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Serv. Res. 40(5), 1297-1317 (2005). doi: 10.1111/j.1475-6773.2005.00420.x (Pubitemid 41442440)
8. Stargardt, T., Schreyögg, J., Busse, R.: Arzneimittelfestbeträ ge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen. Gesundheitswesen 67(7), 468-477 (2005). doi: 10.1055/s-2005-858485 (Pubitemid 41243047)
9. Schneeweiss, S., Soumerai, S., Glynn, R., Maclure, M., Dormuth, C., Walker, A.: Impact of reference-based pricing for angiotensin- converting enzyme inhibitors on drug utilization. CMAJ 166(6), 737-745 (2002)
10. Federal Joint Committee. Explanatory statements on the grouping of statins. Germany, Federal Joint Committee (2004)
11. IQWIG: Nutzenbewertung der Statine unter besonderer Berücksichtigung von Atorvastatin. Institute for Quality and Efficiency in Health Care [IQWIG], Köln (2005)
12. Sikka, R., Xia, F., Aubert, R.: Estimating medication persistency using administrative claims data. Am. J. Manag. Care 11(7), 449-457 (2005)
13. Gibson, T., Mark, T., McGuigan, K.A., Axelsen, K., Wang, S.: The effects of prescription drug copayments on statin adherence. Am. J. Manag. Care 12(9), 509-517 (2006)
14. Avorn, J., Monette, J., Lacour, A., Bohn, R., Monane, M., Mogun, H., LeLorier, J.: Persistence of use of lipid-lowering medications. JAMA 279(18), 1458-1462 (1998). doi:10.1001/ jama.279.18.1458
15. Schneeweiss, S., Patrick, A., Maclure, M., Dormuth, C., Glynn, R.: Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction. Circulation 115(16), 2128-2135 (2007). doi:10.1161/CIRCULATIONAHA. 106.665992
16. Bertrand, M., Duflo, E., Mullainathan, S.: How much should we trust differences-in-differences estimates? Q. J. Econ. 119(1), 249-275 (2004). doi:10.1162/003355304772839588 (Pubitemid 38361206)
17. Motheral, B., Fairman, K.: The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin. Ther. 19(2), 346-366 (1997). doi:10.1016/S0149-2918(97)80122-1 (Pubitemid 27239651)
18. Schneeweiss, S., Maclure, M., Walker, A., Grootendorst, P., Soumerai, S.: On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy 55(2), 97-109 (2001). doi: 10.1016/S0168-8510(00)00120-2 (Pubitemid 32037121)
19. Aldrich, J., Nelson, F.: Linear Probability, Logit, and Probit Models. SAGE, Beverly Hills (1984)
20. Liao, T.: Interpreting Probability Models, Logit, Probit and Other Generalized Linear Models. SAGE, Thousand Oaks, CA (1994)
21. Hoetker, G.: The use of logit and probit models in strategic management research: critical issues. Strateg. Manage. J. 28331-28343 (2007)
22. Busse, R., Riesberg, A.: Health Care System in Transition- Germany. European Observatory on Health Systems and Policies, Copenhagen (2004)
23. Nink, K., Schröder, H.: Ergänzende statistische Übersicht. In: Schwabe, U., Paffrath, D. (eds.) Arzneiverordnungsreport 2005, pp. 1053-1156. Springer, Heidelberg (2006)
24. Motheral, B., Fairman, K.: Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med. Care 39(12), 1293-1304 (2001). doi:10.1097/00005650- 200112000-200200005
25. Gibson, T., McLaughin, C., Smith, D.: A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry 42(3), 293-310 (2005)
26. Nair, K., Valuck, R., Allen, R., Lewis, S.: Impact of increased copayments on the discontinuation/switching rates of nonformulary medications. J. Pharm. Technol. 21(3), 137-143 (2005)
27. Danzon, P.M.: Reference pricing: theory and evidence. In: López-Casasnovas, G., Jönsson, B. (eds.) Reference Pricing and Pharmaceutical Policy, pp. 86-126. Barcelona: Springer, (2001)
28. Busse, R., Schreyögg, J., Henke, K.-D.: Pharmaceutical Regulation in Germany: improving efficiency and controlling expenditures. Int. J. Health Plann. Manage. 20(4), 329-349 (2005). doi: 10.1002/hpm.818 (Pubitemid 41781487)
29. Steiner, J., Prochazka, A.: The asessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. 50(1), 105-116 (1997). doi:10.1016/S0895- 4356(96)00268-275
30. Nink, K., Schröder, H.: Ergänzende statistische Übersicht. In: Schwabe, U., Paffrath, D. (eds.) Arzneiverordnungsreport 2006, pp. 981-1082. Springer, Heidelberg (2007)